Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.

MLA

Armstrong, April, et al. “Continued Treatment with Dupilumab Is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.” Dermatology and Therapy, vol. 12, no. 1, Jan. 2022, pp. 195–202. EBSCOhost, https://doi.org/10.1007/s13555-021-00643-4.

APA

Armstrong, A., Blauvelt, A., Simpson, E. L., Smith, C. H., Herranz, P., Kataoka, Y., Seo, S. J., Ferrucci, S. M., Chao, J., Chen, Z., Rossi, A. B., Shumel, B., & Tomondy, P. (2022). Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. Dermatology and Therapy, 12(1), 195–202. https://doi.org/10.1007/s13555-021-00643-4

Chicago

Armstrong, April, Andrew Blauvelt, Eric L Simpson, Catherine H Smith, Pedro Herranz, Yoko Kataoka, Seong Jun Seo, et al. 2022. “Continued Treatment with Dupilumab Is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment.” Dermatology and Therapy 12 (1): 195–202. doi:10.1007/s13555-021-00643-4.